We are live on
!
Find out more
EP
Eversept Partners Portfolio holdings
AUM
$1.93B
Turnover
41.06%
1-Year Est. Return
160.8%
This Fund
S&P 500
This Quarter
Est. Return
+50.47%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$566M
AUM Growth
+$244M
(+76%)
Cap. Flow
+$79.7M
Cap. Flow
% of AUM
14.07%
Top 10 Holdings %
Top 10 Hldgs %
52.72%
Holding
83
New
26
Increased
22
Reduced
20
Closed
11
Avg Time Held Equity + Options
0.7
years
Top 10 Avg Time Held Equity + Options
0.8
years
Top 20 Avg Time Held Equity + Options
0.7
years
Avg Time Held Equity only
0.7
years
Top 10 Avg Time Held Equity only
0.8
years
Top 20 Avg Time Held Equity only
0.7
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BioCryst Pharmaceuticals
BCRX
|
+$10.7M |
| 2 |
Sanofi
SNY
|
+$9.45M |
| 3 |
ChemoCentryx, Inc.
CCXI
|
+$9.01M |
| 4 |
Pennant Group
PNTG
|
+$8.5M |
| 5 |
MDCO
Medicines Co
MDCO
|
+$7.63M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amarin Corp
AMRN
|
+$7.86M |
| 2 |
Alnylam Pharmaceuticals
ALNY
|
+$7.4M |
| 3 |
ZGNX
Zogenix, Inc.
ZGNX
|
+$6.78M |
| 4 |
DexCom
DXCM
|
+$6.17M |
| 5 |
ABMD
Abiomed Inc
ABMD
|
+$5.33M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 82.4% |
| 2 | Miscellaneous | 13.14% |
| 3 | Real Estate | 1.69% |
| 4 | Communication Services | 1.29% |
| 5 | Industrials | 0.96% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
76
Savara
SVRA
$916M
| – | – |
-316,679
| Closed | -$839K | – |
|
77
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
| – | – |
-30,331
| Closed | -$434K | – |
|
|
IVC
78
DELISTED
Invacare Corporation
IVC
| – | – |
-129,361
| Closed | -$970K | – |
|
|
TCDA
79
DELISTED
Tricida, Inc. Common Stock
TCDA
| – | – |
-65,568
| Closed | -$2.02M | – |
|
|
ABMD
80
DELISTED
Abiomed Inc
ABMD
| – | – |
-29,950
| Closed | -$5.33M | – |
|
|
AIMT
81
CALL
DELISTED
Aimmune Therapeutics
AIMT
| – | – |
-9,100
| Closed | -$191K | – |
|
|
AIMT
82
PUT
DELISTED
Aimmune Therapeutics
AIMT
| – | – |
-10,000
| Closed | -$209K | – |
|
|
ARQL
83
DELISTED
Arqule Inc
ARQL
| – | – |
-412,388
| Closed | -$2.96M | – |
|
Similar funds
SWM
RIA
SI
SG
DCP
SI
MFM
FWP
Eversept Partners's Q4 2019 Portfolio in Review
As of Q4 2019, Eversept Partners held 83 positions worth $566M, up 76% from $322M the previous quarter. Its ten largest holdings account for 53% of the portfolio.
Eversept Partners deployed $79.7M of net new capital in Q4 2019, opening 26 new positions and adding to 22 existing holdings. Its largest new stake was ChemoCentryx, Inc.: 513,189 shares worth $20.3M.
By sector, the portfolio is most concentrated in Healthcare at 82% of assets, down from 90% a quarter earlier, followed by Miscellaneous and Real Estate.
On the sell side, the largest reduction was Amarin Corp, an estimated $7.86M trimmed.
- Eversept Partners's largest Q4 2019 buy was ChemoCentryx, Inc.: 513,189 shares worth $20.3M.
- Eversept Partners added most to BioCryst Pharmaceuticals in Q4 2019, an estimated $10.7M increase.
- Eversept Partners's biggest Q4 2019 reduction was Amarin Corp, cutting an estimated $7.86M.
- Eversept Partners fully exited Alnylam Pharmaceuticals in Q4 2019, selling an estimated $7.4M.
- Eversept Partners's ten largest holdings make up 53% of its $566M portfolio in Q4 2019.
- Eversept Partners opened 26 new positions and closed 11 in Q4 2019.
- Eversept Partners's portfolio value rose 76% quarter-over-quarter to $566M.
Based on Eversept Partners's 13F filing for Q4 2019, filed 13 Feb 2020.